- Home
- LXRX vs CBLL Comparison
LXRX vs CBLL Comparison
Compare LXRX & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXRX | CBLL |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | 300 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.3M | 726.2M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXRX | CBLL |
|---|---|---|
| Price | $2.35 | $18.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.15 | ★ $23.20 |
| AVG Volume (30 Days) | ★ 4.5M | 383.6K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | $29.57 |
| Revenue Next Year | N/A | $28.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $1.00 | $10.85 |
| 52 Week High | $2.68 | $24.33 |
Technical Indicators
Market Signals| Indicator | LXRX | CBLL |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 39.89 |
| Support Level | $1.52 | $17.10 |
| Resistance Level | $2.53 | $19.35 |
| Average True Range (ATR) | 0.13 | 0.66 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 76.25 | 0.00 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About CBLL CeriBell Inc.
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.